Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice

AIDS

Volumn 26, Issue 17, 2012, Pages 2135-2144

  Dash, Prasanta K ^a   Gendelman, Howard E ^a   Roy, Upal ^a   Balkundi, Shantanu ^a   Alnouti, Yazen ^b   Mosley, Rodney L ^a   Gelbard, Harris A ^c   McMillan, Joellyn ^a   Gorantla, Santhi ^a   Poluektova, Larisa Y ^a  

^a NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

central nervous system; drug biodistribution; HIV 1; HIV associated neurocognitive disorders; humanized mice; nanoformulated antiretroviral therapy

Indexed keywords

ATAZANAVIR; LONG ACTING DRUG; MICROTUBULE ASSOCIATED PROTEIN 2; NANOCRYSTAL; NEUROFILAMENT PROTEIN; POLOXAMER; RITONAVIR; SYNAPTOPHYSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; BRAIN REGION; CD34 SELECTION; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG POTENCY; HEMATOPOIETIC STEM CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HIV ASSOCIATED DEMENTIA; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOHISTOCHEMISTRY; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS LOAD; VIRUS RESISTANCE;

ANIMALS; ANTI-HIV AGENTS; ANTIGENS, CD34; BRAIN; DOSAGE FORMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HIV-1; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED NOD; NANOPARTICLES; OLIGOPEPTIDES; PYRIDINES; RITONAVIR; VIRAL LOAD;

EID: 84869498397     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328357f5ad     Document Type: Article

References (35)

1. Volberding PA, Deeks SG. Antiretroviral therapy and management of HIV infection. Lancet 2010; 376:49-62.
2. Swindells S, Flexner C, Fletcher CV, Jacobson JM. The critical need for alternative antiretroviral formulations, and obstacles to their development. J Infect Dis 2011; 204:669-674.
3. Kadiu I, Nowacek A, McMillan J, Gendelman HE. Macrophage endocytic trafficking of antiretroviral nanoparticles. Nanomedicine (Lond) 2011; 6:975-994.
4. Mallipeddi R, Rohan LC. Progress in antiretroviral drug delivery using nanotechnology. Int J Nanomed 2010; 5:533-547.
5. Nowacek AS, Miller RL, McMillan J, Kanmogne G, Kanmogne M, Mosley RL, et al. NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery. Nanomedicine (Lond) 2009; 4:903-917.
6. Wilkin TJ, McKinnon JE, DiRienzo AG, Mollan K, Fletcher CV, Margolis DM, et al. Regimen simplification to atazanavir- ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes. J Infect Dis 2009; 199:866-871.
7. Swindells S, DiRienzo AG, Wilkin T, Fletcher CV, Margolis DM, Thal GD, et al. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. JAMA 2006; 296:806-814.
8. Balkundi S, Nowacek AS, Veerubhotla RS, Chen H, Martinez- Skinner A, Roy U, et al. Comparative manufacture and cell-based delivery of antiretroviral nanoformulations. Int J Nanomed 2011; 6:3393-3404.
9. Balkundi S, Nowacek AS, Roy U, Martinez-Skinner A, McMillan J, Gendelman HE. Methods development for blood borne macrophage carriage of nanoformulated antiretroviral drugs. J Vis Exp 2010; (46): 2460. doi: 10.3791/2460.
10. Nowacek AS, Balkundi S, McMillan J, Roy U, Martinez-Skinner A, Mosley RL, et al. Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages. J Control Release 2011; 150:204-211.
11. Sato K, Koyanagi Y. The mouse is out of the bag: insights and perspectives on HIV-1-infected humanized mouse models. Exp Biol Med (Maywood) 2011; 236:977-985.
12. Berges BK, Rowan MR. The utility of the new generation of humanized mice to study HIV-1 infection: transmission, prevention, pathogenesis, and treatment. Retrovirology 2011; 8:65.
13. Gorantla S, Sneller H, Walters L, Sharp JG, Pirruccello SJ, West JT, et al. Human immunodeficiency virus type 1 pathobiology studied in humanized BALB/cSRag2S/SgammacS/S mice. J Virol 2007; 81:2700-2712.
14. Stoddart CA, Bales CA, Bare JC, Chkhenkeli G, Galkina SA, Kinkade AN, et al. Validation of the SCID-hu Thy/Liv mouse model with four classes of licensed antiretrovirals. PLoS One 2007; 2:e655.
15. Choudhary SK, Rezk NL, Ince WL, Cheema M, Zhang L, Su L, et al. Suppression of human immunodeficiency virus type 1 (HIV-1) viremia with reverse transcriptase and integrase inhibitors, CD4R T-cell recovery, and viral rebound upon interruption of therapy in a new model for HIV treatment in the humanized Rag2S/S{gamma}cS/S mouse. J Virol 2009; 83:8254-8258.
16. Huang J, Gautam N, Bathena SP, Roy U, McMillan J, Gendelman HE, et al. UPLC-MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in mouse serum and tissues. J Chromatogr B Analyt Technol Biomed Life Sci 2011; 879:2332-2338.
17. Dash PK, Gorantla S, Gendelman HE, Knibbe J, Casale GP, Makarov E, et al. Loss of neuronal integrity during progressive HIV-1 infection of humanized mice. J Neurosci 2011; 31:3148- 3157.
18. Poluektova LY, Munn DH, Persidsky Y, Gendelman HE. Generation of cytotoxic T cells against virus-infected human brain macrophages in a murine model of HIV-1 encephalitis. J Immunol 2002; 168:3941-3949.
19. Boffito M, Jackson A, Amara A, Back D, Khoo S, Higgs C, et al. Pharmacokinetics of once-daily darunavir-ritonavir and atazanavir- ritonavir over 72 h following drug cessation. Antimicrob Agents Chemother 2011; 55:4218-4223.
20. Kuypers DR. Immunotherapy in elderly transplant recipients: a guide to clinically significant drug interactions. Drugs Aging 2009; 26:715-737.
21. Bartlett JA, Shao JF. Successes, challenges, and limitations of current antiretroviral therapy in low-income and middleincome countries. Lancet Infect Dis 2009; 9:637-649.
22. Jain R, Clark NM, Diaz-Linares M, Grim SA. Limitations of current antiretroviral agents and opportunities for development. Curr Pharm Des 2006; 12:1065-1074.
23. Nowacek A, Kosloski LM, Gendelman HE. Neurodegenerative disorders and nanoformulated drug development. Nanomedicine (Lond) 2009; 4:541-555.
24. Nowacek A, Gendelman HE. NanoART, neuroAIDS and CNS drug delivery. Nanomedicine (Lond) 2009; 4:557-574.
25. Kanmogne GD, Singh S, Roy U, Liu X, McMillan J, Gorantla S, et al. Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells. Int J Nanomed 2012; 7:2373-2388.
26. Roy U, McMillan J, Alnouti Y, Gautam N, Smith N, Balkundi S, et al. Pharmacodynamic and antiretroviral activities of combination nanoformulated antiretrovirals in HIV-1-infected human PBL-reconstituted mice. J Infect Dis (in press).
27. Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 2009; 41:67-76.
28. Felmlee MA, Lon HK, Gonzalez FJ, Yu AM. Cytochrome P450 expression and regulation in CYP3A4/CYP2D6 double transgenic humanized mice. Drug Metab Dispos 2008; 36:435- 441.
29. Gorantla S, Gendelman HE, Poluektova LY. Can humanized mice reflect the complex pathobiology of HIV-associated neurocognitive disorders? J Neuroimmune Pharmacol 2012; 7:352-362.
30. Gorantla S, Makarov E, Finke-Dwyer J, Castanedo A, Holguin A, Gebhart CL, et al. Links between progressive HIV-1 infection of humanized mice and viral neuropathogenesis. Am J Pathol 2010; 177:2938-2949.
31. Gorantla S, Poluektova L, Gendelman HE. Rodent models for HIV-associated neurocognitive disorders. Trends Neurosci 2012; 35:197-208.
32. Chun TW, Nickle DC, Justement JS, Meyers JH, Roby G, Hallahan CW, et al. Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis 2008; 197:714-720.
33. Choi A, Scherzer R, Bacchetti P, Tien PC, Saag MS, Gibert CL, et al. Cystatin C, albuminuria, and 5-year all-cause mortality in HIV-infected persons. Am J Kidney Dis 2010; 56:872-882.
34. Foreman O, Kavirayani AM, Griffey SM, Reader R, Shultz LD. Opportunistic bacterial infections in breeding colonies of the NSG mouse strain. Vet Pathol 2011; 48:495-499.
35. Taiwo B, Murphy RL, Katlama C. Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results. Drugs 2010; 70:1629-1642.